학술논문

Machine learning integration of circulating and imaging biomarkers for explainable patient-specific prediction of cardiac events: A prospective study
Document Type
article
Source
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Bioengineering
Clinical Research
Biomedical Imaging
Cardiovascular
Heart Disease
Prevention
Heart Disease - Coronary Heart Disease
4.1 Discovery and preclinical testing of markers and technologies
4.2 Evaluation of markers and technologies
Detection
screening and diagnosis
Good Health and Well Being
Aged
Biomarkers
Coronary Angiography
Coronary Artery Disease
Coronary Vessels
Female
Humans
Machine Learning
Male
Middle Aged
Predictive Value of Tests
Prospective Studies
Risk Assessment
Risk Factors
Vascular Calcification
Machine learning
Artificial intelligence
Serum biomarkers
Cardiac computed tomography
Cardiovascular risk stratification
Cardiorespiratory Medicine and Haematology
Cardiovascular System & Hematology
Cardiovascular medicine and haematology
Clinical sciences
Language
Abstract
Background and aimsWe sought to assess the performance of a comprehensive machine learning (ML) risk score integrating circulating biomarkers and computed tomography (CT) measures for the long-term prediction of hard cardiac events in asymptomatic subjects.MethodsWe studied 1069 subjects (age 58.2 ± 8.2 years, 54.0% males) from the prospective EISNER trial who underwent coronary artery calcium (CAC) scoring CT, serum biomarker assessment, and long-term follow-up. Epicardial adipose tissue (EAT) was quantified from CT using fully automated deep learning software. Forty-eight serum biomarkers, both established and novel, were assayed. An ML algorithm (XGBoost) was trained using clinical risk factors, CT measures (CAC score, number of coronary lesions, aortic valve calcium score, EAT volume and attenuation), and circulating biomarkers, and validated using repeated 10-fold cross validation.ResultsAt 14.5 ± 2.0 years, there were 50 hard cardiac events (myocardial infarction or cardiac death). The ML risk score (area under the receiver operator characteristic curve [AUC] 0.81) outperformed the CAC score (0.75) and ASCVD risk score (0.74; both p = 0.02) for the prediction of hard cardiac events. Serum biomarkers provided incremental prognostic value beyond clinical data and CT measures in the ML model (net reclassification index 0.53 [95% CI: 0.23-0.81], p